Drug Research
Drug Discovery & Development

ELC Group partners with PSR Group for advanced drug development

Published 25 January 2017

Global life sciences partner ELC Group is collaborating with New Zealand-based research and development firm Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.

Under the initial terms of the partnership, ELC Group has commissioned PSR Group to develop 10 new products for human use, targeting therapeutic areas including oncology, pain management, antibiotics, antibacterials, cardiovascular and diabetes.

ELC Group is commissioning the new products based on its Concept to Commercialisation process, with plans to market the products in key regions including the US, Europe, Latin America, Russia, the Middle East and China.  The first product from this partnership is expected to be delivered in late 2017.

Through its collaboration with the University of Auckland, PSR Group harnesses state-of-the-art lab facilities and skilled scientists to develop advanced products – from solids and semi-solids to suspension and small injectibles, through to drug delivery systems and advanced therapies.

PSR Group’s research and development programme will harness the University of Auckland’s own inventions, technologies and delivery platforms and combine them with its own research to create highly advanced pharmaceutical products for ELC Group. 

The University of Auckland – New Zealand’s largest university and consistently ranked in the world’s top one percent of institutions for clinical, pre-clinical and health research – specialises in advanced therapies for oncology and opthalmics, plus the development of drug delivery platforms that combine drug and medical devices, including nano and liposome solutions.

ELC Group CEO Marco Rubinstein said: “PSR Group was the stand-out choice as our drug development partner, due to the company’s significant skills and expertise, plus its unique access to key scientific resources at the University of Auckland.”

He added:  “The move into drug development is a natural progression for ELC Group, based on increasing demand for a broader range of services from our long-term clients.  Our business now spans the entire pharmaceutical process, from planning and developing new products, to registration and commercialisation of products in differently developed markets of the world.”

PSR Group CEO Akhil Jain said: “PSR Group is building a world-class capability for the development of technically challenging, proprietary and generic pharmaceutical products.  We are excited to be working together to create an exceptional portfolio of products that can be introduced into the market via ELC Group’s proven commercialisation process and deliver long-term impact on health outcomes.”



Source: Company Press Release